丹参酮Ⅱ_A磺酸钠治疗冠心病心绞痛疗效的系统评价  

Therapeutic Efficacy of Sodium Tanshinone Ⅱ_A Sulfonate in the Treatment of Angina Pectoris:a Systematic Review

作　　者：黄芳[1] 李玲[2] 徐宏彬[2] 

机构地区：[1]安徽中医药大学药学院,合肥230038 [2]同济大学附属第十人民医院,上海200072

出　　处：《中国药房》2015年第9期1225-1228,共4页China Pharmacy

摘　　要：目的:系统评价丹参酮ⅡA磺酸钠(STS)治疗冠心病心绞痛的疗效,以为临床治疗提供循证参考。方法:计算机检索Medline、EMBase、中国Cochrane中心临床对照试验资料数据库、中国生物医学文献数据库和中国中医药科技文献数据库,收集STS治疗冠心病心绞痛疗效的随机对照试验(RCT),对符合纳入标准的文献进行资料提取和质量评价后,采用Rev Man 4.3统计软件进行Meta分析。结果:共纳入60项RCT,合计5 552例患者。Meta分析结果显示,加用STS能显著提高冠心病患者的临床症状有效率[OR=3.64,95%CI(3.12,4.25),P<0.000]和心电图有效率[OR=3.68,95%CI(2.94,4.59),P<0.000]。结论:STS能显著改善冠心病患者的临床症状和心电图。但由于纳入研究质量偏低,该结论有待设计严格的、大规模的RCT进一步证实。OBJECTIVE：To evaluate therapeutic efficacy of sodium tanshinone ⅡAsulfonate（STS）in the treatment of angina pectoris of coronary heart disease,and to provide evidence-based reference for clinical treatment. METHODS：Retrieved from Medline,EMBase,Cochrane Controlled Trials Register,CBM and TCMLRS,randomized controlled trials（RCTs）about STS in the treatment of angina pectoris of coronary heart disease were collected,and Rev Man 4.3 software was used for systematic evaluation after extracting data and evaluating quality of included literatures which met the inclusion criteria. RESULTS：A total of 60 RCTs were included involving 5 552 patients. Results of Meta-analysis showed that STS could improve clinical symptoms[OR=3.64,95%CI（3.12,4.25）,P〈0.000] and electrocardiogram [OR=3.68,95%CI（2.94,4.59）,P〈0.000] of patients with coronary heart disease.CONCLUSIONS：STS is effective in the treatment of angina pectoris of coronary heart disease,and can improve clinical symptoms and electrocardiogram. Due to low quality of included literatures,strict-design and large-scale RCTs are required for further validation of the conclusions.

关 键 词：丹参酮ⅧA磺酸钠 冠心病 心绞痛 系统评价 疗效 

分 类 号：R331.31[医药卫生—人体生理学]